Investigating PRO-C3 as a Biomarker for Liver Damage in NAFLD

Understanding Non-Alcoholic Fatty Liver Disease

A collaborative effort by international researchers has examined the potential of PRO-C3 as a biomarker for predicting liver damage in patients suffering from non-alcoholic fatty liver disease (NAFLD). This condition, often referred to as fatty liver, is characterized by the accumulation of fatty tissue that constitutes more than 5% of the liver in individuals who consume little or no alcohol. The primary contributors to NAFLD include obesity and a sedentary lifestyle. With a global prevalence estimated at 25%, NAFLD is recognized as the leading cause of chronic liver injury.

NAFLD typically initiates with fat accumulation in the liver, which may result in further damage and fibrosis. Over time, a scarred liver may shrink and elevate the risk of liver failure and cancer. Additionally, NAFLD is associated with an increased likelihood of developing type 2 diabetes and cardiovascular diseases.

The Importance of Early Detection and Treatment

Early identification and management of fibrosis are crucial for preventing irreversible liver damage and related health risks. It is essential to differentiate patients with early-stage disease from those at higher risk for liver complications. While liver inflammation is a key factor in liver damage, research indicates that the fibrosis stage serves as the most reliable indicator of overall mortality, liver-related mortality, and the need for transplantation.

Currently, the gold standard for assessing liver fibrosis is through percutaneous needle biopsy; however, there is a critical need for non-invasive tools that can effectively evaluate advanced fibrosis and liver damage in NAFLD patients.

The Role of PRO-C3 in NAFLD

Research Study Overview

Recent investigations have suggested that PRO-C3, previously identified as a fibrosis marker in chronic Hepatitis C patients, may have implications for those with NAFLD. Researchers from the Westmead Institute for Medical Research, Westmead Hospital, and the University of Sydney conducted a study to explore PRO-C3’s potential in assessing liver damage and fibrosis in NAFLD patients. The findings were published in the journal Hepatology.

The study encompassed 431 patients from Australia, Japan, and the United Kingdom. Researchers employed an Enzyme-Linked Immunosorbent Assay (ELISA) to measure PRO-C3 levels in two substantial cohorts of 150 and 281 patients. This data was integrated with routine clinical parameters, including age, diabetes presence, and platelet count, aiming to create a precise tool for identifying liver damage and advanced fibrosis in NAFLD patients.

Findings on PRO-C3 Levels and Fibrosis Staging

The study’s results indicated that PRO-C3 levels rose in correlation with the severity of liver fibrosis and were independently associated with advanced fibrosis. The PRO-C3 algorithm demonstrated superiority over existing fibrosis assessment tools, such as the aspartate aminotransferase (AST) to platelet ratio index (APRI), FIB-4, and the NAFLD fibrosis score (NFS).

Implications of the PRO-C3 Based Score

The research concluded that a score derived from PRO-C3, termed “ADAPT,” effectively identifies liver damage and scarring in NAFLD patients. This tool could enhance the management and treatment of risks linked to NAFLD. Future studies are recommended to investigate whether classifying patients using ADAPT, followed by measuring liver stiffness, could eliminate the necessity for liver biopsies as the diagnostic standard for NAFLD.

References

Daniels, S.J., Leeming, D.J., Eslam, M., Hashem, A.M., Nielsen, M.J., Krag, A., Karsdal, M.A., Grove, J.I., Guha, I.N., Kawaguchi, T. and Torimura, T., 2018. ADAPT: An algorithm incorporating PRO‐C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. The Westmead Institute. New tool to detect fatty liver disease before liver damage. https://www.westmeadinstitute.org.au/news-and-events/2018/new-tool-to-detect-fatty-liver-disease-before-live.